HIV Vaccines Market Research Report by Antibodies, Type, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

HIV Vaccines Market Research Report by Antibodies, Type, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States HIV Vaccines Market size was estimated at USD 74.98 million in 2021 and expected to reach USD 101.71 million in 2022, and is projected to grow at a CAGR 38.08% to reach USD 519.77 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the HIV Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Antibodies, the market was studied across Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, and Mupirocin Ointment.

Based on Type, the market was studied across Acute Paronychia, Candidal Paronychia, Chronic Paronychia, and Pyogenic Paronychia.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for HIV Vaccines market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the HIV Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States HIV Vaccines Market, including AlphaVax, Inc., Antigen Express, Inc., Argo Therapeutics, Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., FIT Biotech, GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline plc, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Novartis AG, Oncolys Biopharma, PaxVax, Profectus Biosciences, Sanofi SA, and TVAX Biomedical.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States HIV Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States HIV Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States HIV Vaccines Market?
4. What is the competitive strategic window for opportunities in the United States HIV Vaccines Market?
5. What are the technology trends and regulatory frameworks in the United States HIV Vaccines Market?
6. What is the market share of the leading vendors in the United States HIV Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the United States HIV Vaccines Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. HIV Vaccines Market, by Antibodies
6.1. Introduction
6.2. Dicloxacillin
6.3. Fusidic Acid Ointment
6.4. Gentamicin Ointment
6.5. Mupirocin Ointment
7. HIV Vaccines Market, by Type
7.1. Introduction
7.2. Acute Paronychia
7.3. Candidal Paronychia
7.4. Chronic Paronychia
7.5. Pyogenic Paronychia
8. California HIV Vaccines Market
8.1. Introduction
9. Florida HIV Vaccines Market
9.1. Introduction
10. Illinois HIV Vaccines Market
10.1. Introduction
11. New York HIV Vaccines Market
11.1. Introduction
12. Ohio HIV Vaccines Market
12.1. Introduction
13. Pennsylvania HIV Vaccines Market
13.1. Introduction
14. Texas HIV Vaccines Market
14.1. Introduction
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AlphaVax, Inc.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Antigen Express, Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Argo Therapeutics
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Argos Therapeutics, Inc.
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Bionor Pharmaceuticals
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Celldex Therapeutics, Inc.
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Crucell N.V.
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. FIT Biotech
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. GeneCure LLC
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Genetic Immunity, Inc.
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. GenVec, Inc.
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. GeoVax Labs, Inc.
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. GlaxoSmithKline plc
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Immune Response BioPharma, Inc.
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Inovio Pharmaceuticals, Inc.
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Novartis AG
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Oncolys Biopharma
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. PaxVax
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Profectus Biosciences
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. Sanofi SA
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
16.21. TVAX Biomedical
16.21.1. Business Overview
16.21.2. Key Executives
16.21.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES HIV VACCINES MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES HIV VACCINES MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES HIV VACCINES MARKET DYNAMICS
FIGURE 8. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY ANTIBODIES, 2027
FIGURE 11. UNITED STATES HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 18. UNITED STATES HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, 2018-2027 (USD MILLION)
FIGURE 22. CALIFORNIA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 23. FLORIDA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 24. ILLINOIS HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 25. NEW YORK HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 26. OHIO HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 27. PENNSYLVANIA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 28. TEXAS HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES HIV VACCINES MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 30. UNITED STATES HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 31. UNITED STATES HIV VACCINES MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES HIV VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2021
TABLE 3. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. CALIFORNIA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 24. CALIFORNIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 25. CALIFORNIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 26. FLORIDA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 27. FLORIDA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 28. FLORIDA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 29. ILLINOIS HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 30. ILLINOIS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 31. ILLINOIS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 32. NEW YORK HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. NEW YORK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 34. NEW YORK HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 35. OHIO HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 36. OHIO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 37. OHIO HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 38. PENNSYLVANIA HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. PENNSYLVANIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 40. PENNSYLVANIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 41. TEXAS HIV VACCINES MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 42. TEXAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 43. TEXAS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44. UNITED STATES HIV VACCINES MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 45. UNITED STATES HIV VACCINES MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 46. UNITED STATES HIV VACCINES MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 47. UNITED STATES HIV VACCINES MARKET RANKING, BY KEY PLAYER, 2021
TABLE 48. UNITED STATES HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2021
TABLE 49. UNITED STATES HIV VACCINES MARKET MERGER & ACQUISITION
TABLE 50. UNITED STATES HIV VACCINES MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 51. UNITED STATES HIV VACCINES MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 52. UNITED STATES HIV VACCINES MARKET INVESTMENT & FUNDING
TABLE 53. UNITED STATES HIV VACCINES MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 54. UNITED STATES HIV VACCINES MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings